This afternoon we watched Exact Sciences drop -2.1% to a price of $46.78 per share. The Mid-Cap Medical Specialities company is now trading -31.76% below its average target price of $68.55. Analysts have set target prices ranging from $54.0 to $90.0 per share for Exact Sciences, and have given the stock an average rating of buy.
Exact Sciences's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.5%. The stock's short ratio is 2.55. Only 0.91% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Another number to watch is the company's rate of institutional share ownership, which now stands at 99.2%. In conclusion, we believe there is mixed market sentiment regarding Exact Sciences.
Institutions Invested in Exact Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | FMR, LLC | 15% | 27,723,546 | $1,296,907,448 |
| 2025-03-31 | Capital World Investors | 9% | 17,835,277 | $834,334,236 |
| 2025-03-31 | Vanguard Group Inc | 9% | 17,637,674 | $825,090,368 |
| 2025-03-31 | Wellington Management Group, LLP | 7% | 12,501,316 | $584,811,547 |
| 2025-03-31 | Blackrock Inc. | 6% | 11,920,721 | $557,651,313 |
| 2025-03-31 | State Street Corporation | 4% | 6,613,899 | $309,398,187 |
| 2025-03-31 | Price (T.Rowe) Associates Inc | 3% | 6,403,872 | $299,573,124 |
| 2025-03-31 | Ameriprise Financial, Inc. | 2% | 3,363,783 | $157,357,764 |
| 2025-03-31 | Mackenzie Financial Corporation | 2% | 3,281,639 | $153,515,068 |
| 2025-03-31 | Geode Capital Management, LLC | 2% | 3,266,439 | $152,804,012 |
